DNTH
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Dianthus Therapeutics, Inc. (DNTH) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (F). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | F (0.0) | C (2.4) | B- (2.9) | C+ (2.6) | C+ (2.6) | C- (2.1) |
| 2026-11-04 | F (0.0) | C+ (2.6) | C+ (2.6) | C+ (2.6) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | F (0.0) | C+ (2.6) | C+ (2.7) | C+ (2.7) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | F (0.0) | C+ (2.6) | C+ (2.7) | C+ (2.7) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | F (0.0) | C+ (2.6) | C+ (2.7) | C+ (2.8) | C+ (2.6) | C- (2.1) |